Recently, it was reported that apoE functions as a checkpoint in controlling the resolution of inflammation by interacting with C1q in the complement activation pathway and subsequently reducing C5 and the inflammatory burden in atherosclerosis and Alzheimer disease [140]. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.